MDAI
外观
临床资料 | |
---|---|
其他名称 | 5,6-Methylenedioxy-2-aminoindane; 5,6-Methylenedioxy-2-aminoindan; Methylenedioxyaminoindane; Methylenedioxyaminoindan |
给药途径 | 口服给药 |
药物类别 | Serotonin–norepinephrine releasing agent; Entactogen |
ATC码 |
|
法律规范状态 | |
法律规范 |
|
药物动力学数据 | |
作用时间 | 2–6 小时 |
识别信息 | |
| |
CAS号 | 132741-81-2 |
PubChem CID | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
化学信息 | |
化学式 | C10H11NO2 |
摩尔质量 | 177.20 g·mol−1 |
3D模型(JSmol) | |
| |
|
MDAI(5,6-亚甲二氧基-2-氨基茚满,英语:5,6-methylenedioxy-2-aminoindane)是一种含氮有机化合物,分子式C10H11NO2,属于2-氨基茚满衍生物,1990年代由普渡大学的David E. Nichols团队开发[2],结构与MDAT类似[3],能作为选择性血清素释放剂(SSRA)[4]。
参考文献
[编辑]- ^ Anvisa. RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial [Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control]. Diário Oficial da União. 2023-07-24 (2023-07-25) [2023-08-27]. (原始内容存档于2023-08-27) (巴西葡萄牙语).
- ^ Johnson MP, Conarty PF, Nichols DE. [3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues. European Journal of Pharmacology. July 1991, 200 (1): 9–16. PMID 1685125. doi:10.1016/0014-2999(91)90659-e.
- ^ Pinterova N, Horsley RR, Palenicek T. Synthetic Aminoindanes: A Summary of Existing Knowledge. Frontiers in Psychiatry (Frontiers Media SA). 17 November 2017, 8: 236. PMC 5698283 . PMID 29204127. doi:10.3389/fpsyt.2017.00236 .
- ^ Sainsbury PD, Kicman AT, Archer RP, King LA, Braithwaite RA. Aminoindanes--the next wave of 'legal highs'?. Drug Testing and Analysis (Wiley). 2011, 3 (7-8): 479–482. PMID 21748859. doi:10.1002/dta.318.